Tumor News and Research

RSS

Depressive symptoms associated with poorer survival in patients with head and neck cancer

In a study of patients with head and neck cancer, even mild depressive symptoms were associated with poorer overall survival.

22 Jan 2018

Researchers develop single blood test that screens for 8 cancer types

Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.

19 Jan 2018

Researchers discover potential target genes to halt thyroid cancer progression

Thyroid cancer is a disease with good cure rates in most cases. In 5% of patients, however, the tumor becomes refractory to the available therapies and may spread all over the body, causing death.

19 Jan 2018

Study reveals key mechanism of how cancer metastasis happens

Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center researchers.

19 Jan 2018

New precision medicine approach for metastatic pancreatic cancer

A three-year grant has been awarded to fund a phase 1b clinical trial of a precision medicine approach to treating metastatic pancreatic cancer.

18 Jan 2018

Modular gene enhancers may be suitable target in treatment of blood cancer

Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer.

18 Jan 2018

Pretreatment improves outcomes in high-risk stage 3 melanoma, study shows

A pair of targeted therapies given before and after surgery for melanoma produced at least a six-fold increase in time to progression compared to standard-of-care surgery for patients with stage 3 disease, researchers at The University of Texas MD Anderson Cancer Center report in Lancet Oncology.

18 Jan 2018

Study to test new precision medicine approach for metastatic pancreatic cancer

The Lustgarten Foundation has awarded Columbia University's Herbert Irving Comprehensive Cancer Center a three-year grant, as part of its Translational Clinical Program, to test a new precision medicine approach to the treatment of metastatic pancreatic cancer.

18 Jan 2018

Analysis finds overlooked crucial factor in determining prognosis for DIPGs

The prognosis for all children diagnosed with an aggressive brain tumor known as diffuse intrinsic pontine glioma and similar tumors has been mostly the same: dismal.

18 Jan 2018

Findings reveal conventional cancer therapy as double-edged sword

Researchers have discovered that killing cancer cells can actually have the unintended effect of fueling the proliferation of residual, living cancer cells, ultimately leading to aggressive tumor progression.

18 Jan 2018

LJI study reveals key player that promotes skin inflammation in atopic dermatitis

Severe eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition that is driven by an allergic reaction. In their latest study, researchers at La Jolla Institute reveal an important player that promotes skin inflammation in atopic dermatitis and the characteristic thickening of the skin.

18 Jan 2018

Novel gene expression analysis technique can accurately and quickly measure RNA

A University of Illinois and Mayo collaboration has demonstrated a novel gene expression analysis technique that can accurately measure levels of RNA quickly and directly from a cancerous tissue sample while preserving the spatial information across the tissue --something that conventional methods cannot do.

18 Jan 2018

Research: Men who lack HSD17B4 gene may be more susceptible to treatment-resistant prostate cancer

Cleveland Clinic researchers have confirmed for the first time a mechanistic link between the gene HSD17B4 and deadly, treatment-resistant prostate cancer.

17 Jan 2018

Researchers identify new anti-inflammatory drug target

A new study suggests that parmodulins may provide anti-inflammatory and anti-thrombotic protection to endothelial cells, without interfering with clotting.

16 Jan 2018

Penn scientists identify new therapeutic target for treatment of melanoma

Researchers in the Perelman School of Medicine at the University of Pennsylvania have identified a new therapeutic target for the treatment of melanoma.

16 Jan 2018

FDA grants approval for first drug to treat inherited breast cancer

The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast cancer that have spread (metastasized) and whose tumors have a specific inherited (germline) genetic mutation, making it the first drug in its class (PARP inhibitor) approved to treat breast cancer, and it is the first time any drug has been approved to treat certain patients with metastatic breast cancer who have a "BRCA" gene mutation.

15 Jan 2018

Scientists describe groundbreaking training effect on the innate immune system

"Training" of precursors of white blood cells leads to a sustained positive response of the hematopoietic system. This effect could help accelerate the formation of new white blood cells, which are vitally needed during chemotherapy, a process that can slow down hematopoiesis.

15 Jan 2018

Researchers develop remote-controlled mechanogenetics system to target and kill cancer cells

A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

15 Jan 2018

Research sheds new light on genetic, environmental factors that promote prostate cancer metastasis

Prostate tumors tend to be what scientists call "indolent" - so slow-growing and self-contained that many affected men die with prostate cancer, not of it. But for the percentage of men whose prostate tumors metastasize, the disease is invariably fatal.

15 Jan 2018

U.S. FDA approves first drug for patients with germline BRCA-mutated metastatic breast cancer

AstraZeneca and Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved LYNPARZA (olaparib) for use in patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting.

12 Jan 2018